Project Grant R01CA314282
Award Date 6/18/26
Completion Date 5/31/31
Dollars Obligated $636K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- Federal Grant Award Summary Emory University received a $402,401 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 6, 2026, with completion targeted for March 31, 2028. The project addresses pancreatic ductal adenocarcinoma (PDAC) resistance to immune checkpoint inhibitors by investigating sex-specific immune mechanisms. The research will deliver scientific findings on how the vasoactive intestinal polypeptide...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a Project Grant of $602,170 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective June 2, 2026, through May 31, 2031. This award supports the development and validation of biomimetic migrating nanoparticles designed to target tumor stroma and neural invasion in pancreatic cancer treatment. The research involves engineering hyaluronic acid nanoparticles (HANPs) conjugated...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $683,970 Project Grant to Columbia University's Health Sciences Division effective April 1, 2026 through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project focuses on developing and evaluating therapeutic approaches to treat pancreatic ductal adenocarcinoma (PDAC) through stromal modification and immune modulation. The research investigates the role of αvβ5 integrin in PDAC...
- Federal Project Grant Award Summary Emory University received a $572,378 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. The award funds fundamental research investigating the metabolic mechanisms that regulate dormancy in disseminated non-small cell lung cancer (NSCLC) subpopulations. The research employs an image-guided genomics approach to examine how collective invasion packs...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $119,858 to the Regents of the University of Minnesota under the Cancer Biology Research program (CFDA 93.396) on August 7, 2025, for a project extending through July 31, 2030. This project grant supports fundamental research aimed at elucidating and overcoming T cell dysfunction in pancreatic ductal adenocarcinoma (PDA), a disease notoriously resistant to immunotherapy. The research program comprises three...
- Federal Grant Award Summary Emory University received a $602,847 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct fundamental research investigating the N-glycan modification pathway as a therapeutic target for breast cancer treatment. The five-year project, which commenced July 1, 2026 and concludes June 30, 2031, focuses on determining the impact of MAN1C1, a glycosyl hydrolase enzyme, on tumor progression, immune evasion,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $156,500 Project Grant on August 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct integrated multi-omics research exploring the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The two-year project, concluding July 31, 2027, will investigate the systemic biological mechanisms underlying cancer cachexia through comprehensive analysis of...
- Federal Grant Award Summary The National Cancer Institute awarded a $411,206 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a completion date of April 30, 2028. This award supports the development of small molecule inhibitors targeting the proton-sensing receptor GPR68 for pancreatic ductal adenocarcinoma (PDAC) therapy. The research addresses a critical clinical need, as PDAC accounts for approximately 90%...
- Federal Grant Award Summary Emory University received a $646,181 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) to conduct a five-year research initiative examining the role of clonal hematopoiesis (CH) in non-small cell lung cancer (NSCLC) development and immune evasion. The award, effective April 2, 2026, through March 31, 2031, supports fundamental cancer biology research aimed at understanding how age-related mutations in...
- Federal Project Grant Award Summary Columbia University's Health Sciences Division, in receipt of a $109,080 Project Grant awarded September 1, 2025, by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), is conducting a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The trial compares a four-drug regimen...